Advances in Brief B 7-1 Expression by a Non-Antigen Presenting Cell-derived Tumor

The existence of a naturally occurring immunosurveillance against neoplastic cells is controversial. A difficulty with this concept is that tumor-specific antigen-reactive T cells would not be expected to become activated after encountering tumor cells, since T cells that bind to antigen in the absence of the «»stimulationprovided by antigen-presenting cells may be inactivated. We studied a transgenic model of tumorigenesis where T cells reactive to a particular tumor-specific antigen are lost prior to the development of non-antigen-presenting cell-derived tumors; therefore, the tumors that develop are not subjected to immunosurveillance. We found that a tumor cell line derived from one such tumor expresses the T-cell costimulatory molecule B7-1, the expression of which is normally re stricted to antigen-presenting cells. In addition, we found that several immortalized cell lines, which are nontumorigenic and thus have suffered only early genetic events in the tumorigenesis process, express B7. This suggests that a host cell can be induced to express surface B7-1 molecules after suffering an oncogenic insult, which might possibly be a primary mechanism of immunosurveillance against tumors.

[1]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 2007, Journal of immunology.

[2]  J. Miller,et al.  Mechanisms of immune tolerance induction through the thymic expression of a peripheral tissue-specific protein. , 1995, International immunology.

[3]  J. Johnston,et al.  Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity , 1994, The Journal of experimental medicine.

[4]  P. Hersey,et al.  Expression of the co‐stimulatory molecule B7 on melanoma cells , 1994, International journal of cancer.

[5]  L. Lanier,et al.  B70 antigen is a second ligand for CTLA-4 and CD28 , 1993, Nature.

[6]  J. Berzofsky,et al.  A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. , 1993, Cancer research.

[7]  J. Allison,et al.  CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help , 1993, The Journal of experimental medicine.

[8]  P. Linsley,et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.

[9]  V. Stewart,et al.  RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement , 1992, Cell.

[10]  P. Linsley,et al.  CTLA-4 is a second receptor for the B cell activation antigen B7 , 1991, The Journal of experimental medicine.

[11]  R. Schwartz,et al.  A cell culture model for T lymphocyte clonal anergy. , 1990, Science.

[12]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.

[13]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[14]  J. DiPaolo,et al.  Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA , 1987, Journal of virology.

[15]  R. Hammer,et al.  Elastase I promoter directs expression of human growth hormone and SV40 T antigen genes to pancreatic acinar cells in transgenic mice. , 1985, Cold Spring Harbor symposia on quantitative biology.

[16]  T. Hünig T-cell function and specificity in athymic mice , 1983 .

[17]  B. Weissman,et al.  BALB and kirsten murine sarcoma viruses alter growth and differentiation of EGF-dependent BALB/c mouse epidermal keratinocyte lines , 1983, Cell.

[18]  J. Rygaard,et al.  The Nude Mouse vs. The Hypothesis of Immunological Surveillance , 1976, Transplantation reviews.

[19]  F. Burnet The concept of immunological surveillance. , 1970, Progress in experimental tumor research.